Antiandrogen News and Research

RSS

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Clinical trials for two compounds show promise in advanced prostate cancer

In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer.

9 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

Hirsutism in premenopausal women - new treatment guidelines

The Endocrine Society has released new clinical practice guidelines for the treatment of hirsutism in premenopausal women. The guidelines appear in the April issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

22 Apr 2008

Abiraterone reduces levels of prostate specific antigen

For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials.

9 Jul 2007

Cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer

A new study finds that a cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer. The results of this clinical trial, led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appear in the August 2005 issue of the Journal of Urology.

26 Jul 2005